Notice of Change of the Locus of Review and Application Types Allowed for PAR-22-035, "Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)"
Notice Number:
NOT-MH-22-075

Key Dates

Release Date:

December 1, 2021

Related Announcements

PAR-22-035 - Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

Issued by

National Institute of Mental Health (NIMH)

Purpose

This notice announces changes to the locus of review of Funding Opportunity Announcement (FOA) PAR-22-035 "Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)" and clarifies the Application Types Allowed.

The following sections of PAR-22-035 has been modified to reflect the revisions to Locus of Review and Application Types Allowed:

Currently Reads:

Section V. Application Review Information

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMH, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

Modified to Read (changes shown in bold italics):

Section V. Application Review Information

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

Currently Reads:

Part 2. Full Text of Announcement

Section II. Award Information

Application Types Allowed:

New
Renewal
Resubmission
Revision

Renewal of RFA-MH-21-105 and PAR-22-035

Resubmission of RFA-MH-21-105 and PAR-22-035

Revision of RFA-MH-21-105 and PAR-22-035

Modified to Read:

Part 2. Full Text of Announcement

Section II. Award Information

Application Types Allowed:

New

Renewal of RFA-MH-21-105 and PAR-22-035

Resubmission of RFA-MH-21-105 and PAR-22-035

Revision of RFA-MH-21-105 and PAR-22-035


All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Laura M. Rowland, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-480-8335
Email: laura.rowland@nih.gov